tetano
Editor, Senior Moderator
Antivir Chem Chemother. 2017 Apr;25(1):11-17. doi: 10.1177/2040206617691885. Epub 2017 Mar 21.
[h=1]Combinations of L-NG-monomethyl-arginine and oseltamivir against pandemic influenza A virus infections in mice.[/h] Smee DF[SUP]1[/SUP], Dagley A[SUP]1[/SUP], Tarbet EB[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] L-N[SUP]G[/SUP]-monomethyl-arginine (L-NMMA) is an experimental compound that suppresses nitric oxide production in animals. The compound was combined with oseltamivir to treat lethal influenza A/California/04/2009 (H1N1) pandemic virus infections in mice. Treatments were given twice a day for five days starting 4 h (oseltamivir, by oral gavage) or three days (L-NMMA, by intraperitoneal route; corresponding to the time previously reported for nitric oxide induction in the animals) after infection. Low doses of oseltamivir were used in order to demonstrate synergy or antagonism. Oseltamivir monotherapy protected 70% of mice from death at 1 mg/kg/day. L-NMMA (40 and 80 mg/kg/day) was ineffective alone in preventing mortality. Compared to oseltamivir treatment alone, L-NMMA combined with oseltamivir was synergistically effective (as evaluated by three-dimensional MacSynergy analysis), resulting in survival increases from 20 to 70% when 40 or 80 mg/kg/day of L-NMMA was combined with 0.3 mg/kg/day of oseltamivir, and from 70 to 100% survival increases when these doses were combined with 1 mg/kg/day of oseltamivir. These data demonstrate that a nitric oxide inhibitor such as L-NMMA has the potential to be beneficial when combined with oseltamivir in treating influenza virus infections.
[h=4]KEYWORDS:[/h] L-NMMA; influenza; mice; oseltamivir; synergy
PMID: 28417640 DOI: 10.1177/2040206617691885
[h=1]Combinations of L-NG-monomethyl-arginine and oseltamivir against pandemic influenza A virus infections in mice.[/h] Smee DF[SUP]1[/SUP], Dagley A[SUP]1[/SUP], Tarbet EB[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] L-N[SUP]G[/SUP]-monomethyl-arginine (L-NMMA) is an experimental compound that suppresses nitric oxide production in animals. The compound was combined with oseltamivir to treat lethal influenza A/California/04/2009 (H1N1) pandemic virus infections in mice. Treatments were given twice a day for five days starting 4 h (oseltamivir, by oral gavage) or three days (L-NMMA, by intraperitoneal route; corresponding to the time previously reported for nitric oxide induction in the animals) after infection. Low doses of oseltamivir were used in order to demonstrate synergy or antagonism. Oseltamivir monotherapy protected 70% of mice from death at 1 mg/kg/day. L-NMMA (40 and 80 mg/kg/day) was ineffective alone in preventing mortality. Compared to oseltamivir treatment alone, L-NMMA combined with oseltamivir was synergistically effective (as evaluated by three-dimensional MacSynergy analysis), resulting in survival increases from 20 to 70% when 40 or 80 mg/kg/day of L-NMMA was combined with 0.3 mg/kg/day of oseltamivir, and from 70 to 100% survival increases when these doses were combined with 1 mg/kg/day of oseltamivir. These data demonstrate that a nitric oxide inhibitor such as L-NMMA has the potential to be beneficial when combined with oseltamivir in treating influenza virus infections.
[h=4]KEYWORDS:[/h] L-NMMA; influenza; mice; oseltamivir; synergy
PMID: 28417640 DOI: 10.1177/2040206617691885